According to literature, the recurrence rate of PCa within 3-5 years after treatment is around 28-34%, mostly presented increased serum prostate-specific antigen (PSA), that is, biochemical recurrence (BCR) [1, 2]. Here, KLK3 is linked to posterior cortical atrophy.